ArticleInternational journal of molecular sciences2025

Structural Insights into the ADCC Mechanism and Resistance of Mogamulizumab, a First-in-Class Anti-CCR4 Therapy for Cutaneous T Cell Lymphoma.

Seung Beom Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.